CELL IMPLANTATION TO PREVENT AND/OR TREAT AUTOIMMUNE DISEASE

• US 20090162325A1
• Filed: 06/07/2006
• Published: 06/25/2009
• Est. Priority Date: 06/08/2005
• Status: Abandoned Application

• Current Assignee: Neurotrophincell Pty, Limited
• Original Assignee: Neurotrophincell Pty, Limited
• Inventors: Tan, Paul Lip Jin, Elliott, Robert Bartlett, Skinner, Stephen John Martin
• Application Number:
  US11/916,963
• Publication Number:
  US 20090162325A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders

Abstract

The present invention is directed to the prevention or treatment of autoimmune diseases, and in particular, of type I diabetes, by administering a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

Claims

1-29. -29. (canceled)

30. A method for preventing onset of type 1 diabetes in a patient at risk thereof, said method comprising administering to said patient a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

31. A method for delaying onset of type 1 diabetes in a patient at risk thereof, said method comprising administering to said patient a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

33. The method of claim 31, wherein said living choroid plexus cells are isolated from an adult, neonatal or fetal donor pig and the implantable composition comprises a xenograft.

34. The method of claim 33, wherein the living choroid plexus cells are isolated from a donor pig aged between −

20 and +20 days.

35. The method of claim 31, wherein the implantable composition further comprises feeder or support cells.

36. The method of claim 35, wherein the feeder or support cells are selected from the group consisting of Sertoli cells, fibroblasts, splenocytes, macrophages and thymocytes.

37. The method of claim 35, wherein the feeder or support cells are isolated from the same donor pig as the choroid plexus cells.

38. The method of claim 31, wherein the implantable composition comprises “

naked”

choroid plexus cells and optionally “

naked”

feeder or support cells.

39. The method of claim 31, wherein the living implantable composition comprises encapsulated choroid plexus cells and optionally encapsulated feeder or support cells.

40. The method of claim 31, wherein the implantable composition is inserted in an implantable device prior to administration to said patient.

41. The method of claim 31, in combination with insulin administration.

42. The method of claim 31, in combination with insulin administration.

32. A method for treating type I or type II diabetes in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

43. The method of claim 32, in combination with insulin administration.

44. A method for preventing or delaying the onset of an autoimmune disease, other than type I diabetes or any neurological autoimmune disease, comprising administering to said patient a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

46. The method of claim 44, wherein said autoimmune disease is Stiff Man syndrome.

47. The method of claim 44, wherein said composition is administered in an implant.

45. A method for treating autoimmune diseases, other than type I diabetes or any neurological autoimmune disease, administering to said patient a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.

48. The method of claim 45, wherein said composition is administered in an implant.